TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31129183

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg zinc gluconate daily for 8 weeks)
Number of subjects: 70
Study: 27036877

Group type: EXPERIMENTAL
Intervention: ID-ISTDP (Internet-delivered intensive short-term dynamic psychotherapy)
Number of subjects: 81

Group type: COMPARATOR
Intervention: In-person ISTDP (intensive short-term dynamic psychotherapy)
Number of subjects: 81
Study: 27990302

Group type: EXPERIMENTAL
Intervention: Deep Neck Flexor (DNF) training
Number of subjects: 67

Group type: COMPARATOR
Intervention: Superficial neck muscle exercise
Number of subjects: 67

Group type: COMPARATOR
Intervention: Advice group
Number of subjects: 67
Study: 24738121

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 69
Study: 21751205

Group type: EXPERIMENTAL
Intervention: Epoetin alpha
Number of subjects: 109

Group type: COMPARATOR
Intervention: No epoetin
Number of subjects: 109
Study: 19581455

Group type: EXPERIMENTAL
Intervention: IV doripenem at 500 mg every 8 hours (q8h)
Number of subjects: 753

Group type: COMPARATOR
Intervention: IV levofloxacin at 250 mg every 24 hours (q24h)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Microbiological modified intent-to-treat cohort (n = 648)
Number of subjects: 753
Study: 17325504

Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 259

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 259
Study: 15125719

Group type: COMPARATOR
Intervention: Biventricular pacing (BIVP)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single-site left ventricular pacing (LVP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: BIVP
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: LVP
Number of subjects: 28
Study: 11772847

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg intravenously)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 9445204

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide hydrochloride (Trusopt)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximum dose of acetazolamide (Diamox)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Small doses of acetazolamide added to dorzolamide treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8010458

Group type: EXPERIMENTAL
Intervention: Demand dose PCEA (3 mL; lockout interval = 10 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous infusion plus demand dose PCEA (3 mL/h and 6 mL/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fixed-rate continuous epidural infusion (CEI) at 12 mL/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All PCEA groups (including demand dose and continuous infusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCEA groups receiving no background infusion or a 3-mL/h background infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCEA groups
Number of subjects: 60
Study: 2644828

Group type: EXPERIMENTAL
Intervention: Nifedipine (60 to 90 mg per day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg per day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 952600

Group type: EXPERIMENTAL
Intervention: Alpha-EEG feedback training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pseudofeedback
Number of subjects: 0
Study: 31860911

Group type: EXPERIMENTAL
Intervention: Pink-neck implant and abutment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gray implant and abutment (control)
Number of subjects: 40
Study: 31042723

Group type: EXPERIMENTAL
Intervention: D-pigment dermocosmetic lightening product
Number of subjects: 36

Group type: COMPARATOR
Intervention: Moisturizing product (control)
Number of subjects: 36
Study: 28840583

Group type: EXPERIMENTAL
Intervention: G‐CSF (5 μg/kg/day, for 6 consecutive days) in addition to standard medical therapy with antiviral drugs
Number of subjects: 32

Group type: COMPARATOR
Intervention: Antiviral drugs alone
Number of subjects: 32
Study: 25573908

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 138

Group type: COMPARATOR
Intervention: Mycophenolate mofetil plus pulse oral dexamethasone
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: APOL1 risk genotype
Number of subjects: 138
Study: 24182660

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 21816379

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 10804

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10804
Study: 18537470

Group type: EXPERIMENTAL
Intervention: High Protein Group (protein drink with additional protein and ginger twice daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Protein Group (protein drink and ginger twice daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control Group (normal diet)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Gastric myoelectrical activity assessment (in 5 patients) after ingestion of high protein meal and ginger
Number of subjects: 28
Study: 15695544

Group type: EXPERIMENTAL
Intervention: Caudal epidural local anaesthetic and steroid treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Targeted epidural local anaesthetic and steroid placement with spinal endoscope
Number of subjects: 60
Study: 12390563

Group type: EXPERIMENTAL
Intervention: Option‐4 algorithm (O‐4)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Modified Option‐4 algorithm (MO‐4)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Option‐3 method (O‐3)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Double Pass method (DP)
Number of subjects: 16
Study: 9895342

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine therapy (11, 22, and 44 mg daily)
Number of subjects: 71
Study: 7769051

Group type: EXPERIMENTAL
Intervention: Nafarelin 200 micrograms twice daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Buserelin 200 micrograms five times daily
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nafarelin 400 micrograms twice daily
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nafarelin 200 micrograms
Number of subjects: 240

Group type: COMPARATOR
Intervention: Buserelin
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nafarelin (either dose)
Number of subjects: 240
Study: 2126222

Group type: EXPERIMENTAL
Intervention: ibopamine-captopril
Number of subjects: 23

Group type: COMPARATOR
Intervention: ibopamine-placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: captopril-placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo-placebo
Number of subjects: 23
Study: 282999

Group type: EXPERIMENTAL
Intervention: Sorbitol (20 g of chocolate with sorbitol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucrose (20 g of chocolate with 40% sucrose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (children living in Budapest)
Number of subjects: 0
Study: 28900715

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) and Transfemoral access (TFA)
Number of subjects: 250
Study: 27857015

Group type: EXPERIMENTAL
Intervention: Web-based preconception health promotion program (6-hour lecture series over 4 weeks)
Number of subjects: 51
Study: 24094613

Group type: EXPERIMENTAL
Intervention: On-site group cognitive behavioral therapy (CBT) for depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care residential treatment
Number of subjects: 0
Study: 23739435

Group type: EXPERIMENTAL
Intervention: Cavinton (25 mg intravenous during 10 days and then 10 mg 3 times daily during 3 months)
Number of subjects: 180
Study: 20837089

Group type: EXPERIMENTAL
Intervention: Laser fluorescence measurements for sound sites (D(0), n=40)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Laser fluorescence measurements for D(0-2) (n=74)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Laser fluorescence values for opened lesions (n=43)
Number of subjects: 117
Study: 18415093

Group type: EXPERIMENTAL
Intervention: Artesunate (4 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amodiaquine (10 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of Artesunate and Amodiaquine
Number of subjects: 15
Study: 16192502

Group type: EXPERIMENTAL
Intervention: MV with Vt = 10 mL/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: MV with Vt = 5 mL/kg
Number of subjects: 32
Study: 12621632

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 21
Study: 10856673

Group type: EXPERIMENTAL
Intervention: Vancomycin 1 g every 12 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vancomycin 1 g every 24 hours
Number of subjects: 0
Study: 9118847

Group type: EXPERIMENTAL
Intervention: Patients with childhood-onset epilepsy
Number of subjects: 176

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Patients receiving AED polytherapy
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Patients receiving AED monotherapy
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Current AED therapy
Number of subjects: 176
Study: 8455969

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Placebo-TENS
Number of subjects: 514

Group type: COMPARATOR
Intervention: Control
Number of subjects: 514
Study: 3541427

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (two doses: one at birth and another 2 months later, plus a booster at 12 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (booster dose at 12 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (two doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonimmunized newborns
Number of subjects: 0
Study: 29672897

Group type: EXPERIMENTAL
Intervention: PF-04965842 3 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 10 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 30 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 400 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 800 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 30 mg QD for 10 days
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg QD for 10 days
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg QD for 10 days
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 400 mg QD for 10 days
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg BID for 10 days
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg BID for 10 days
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 26035523

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 to 450 mg/d)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 26995811

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) integrated with dental treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Adapted dental treatment
Number of subjects: 55
Study: 22999067

Group type: EXPERIMENTAL
Intervention: ETT size 6.0 with lidocaine (Group D)
Number of subjects: 240

Group type: COMPARATOR
Intervention: ETT size 7.0 with saline (Group A)
Number of subjects: 240

Group type: COMPARATOR
Intervention: ETT size 6.0 with saline (Group B)
Number of subjects: 240

Group type: COMPARATOR
Intervention: ETT size 7.0 with lidocaine (Group C)
Number of subjects: 240
Study: 20593634

Group type: EXPERIMENTAL
Intervention: Minocycline microspheres plus scaling and root planing
Number of subjects: 127

Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 127
Study: 18794556

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 380

Group type: COMPARATOR
Intervention: Simple touch (control)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Both groups (massage and control)
Number of subjects: 380
Study: 15752945

Group type: EXPERIMENTAL
Intervention: Losartan low-dose (2.5/5.0 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Losartan middle-dose (25/50 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Losartan high-dose (50/100 mg)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Switch from middle-dose losartan to placebo
Number of subjects: 175

Group type: COMPARATOR
Intervention: Switch from high-dose losartan to placebo
Number of subjects: 175

Group type: COMPARATOR
Intervention: Switch from low-dose losartan to placebo
Number of subjects: 175
Study: 11919526

Group type: EXPERIMENTAL
Intervention: Oral ondansetron
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 10375429

Group type: EXPERIMENTAL
Intervention: Elastoviscous 0.1% Hylan A solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 8884589

Group type: EXPERIMENTAL
Intervention: Specialist community service 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specialist community service 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-referred sample
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staff morale
Number of subjects: 0
Study: 1464864

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (3.8 g of eicosapentaenoic acid plus 2.0 g of docosahexaenoic acid) and naproxen (750 mg/day for 16 weeks)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (as Group 2) and naproxen (as Group 1)
Number of subjects: 67

Group type: COMPARATOR
Intervention: corn oil (placebo omega-3 fatty acids, 7 g/day for 16 weeks) and naproxen (750 mg/day for 10 weeks followed by stepwise reduction)
Number of subjects: 67
Study: 6498042

Group type: EXPERIMENTAL
Intervention: Cuffed p.v.c. tracheal tubes
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Red rubber tracheal tubes
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intermittent adjustment of cuff volume
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Humidification of inspired gases
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Anaesthetists unaware of the trial
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 80
Study: 29734211

Group type: EXPERIMENTAL
Intervention: Early colonoscopy (<24 hours)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard colonoscopy (1 to 3 days)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 132
Study: 29277856

Group type: EXPERIMENTAL
Intervention: HA-irinotecan (HA-IR) + Carboplatin (C)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Irinotecan (IR) + Carboplatin (C)
Number of subjects: 34
Study: 27854314

Group type: EXPERIMENTAL
Intervention: Black tea (150 mg polyphenols)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 23601079

Group type: EXPERIMENTAL
Intervention: Additional radiofrequency ablation (RFCA) for spontaneous dissociated pulmonary vein activity (DPV‐spike) after pulmonary vein isolation (PVI)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Only pulmonary vein isolation (PVI)
Number of subjects: 152
Study: 21742098

Group type: EXPERIMENTAL
Intervention: Pre-Fontan coil embolization of APCs
Number of subjects: 539

Group type: COMPARATOR
Intervention: No pre-Fontan coil embolization of APCs
Number of subjects: 539
Study: 19130903

Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uterosacral vaginal vault suspension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral techniques and pelvic floor muscle training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 16739841

Group type: EXPERIMENTAL
Intervention: Local single-point electroacupuncture stimulation
Number of subjects: 98

Group type: COMPARATOR
Intervention: Routine electroacupuncture stimulation
Number of subjects: 98
Study: 15001605

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily (group 1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg twice weekly (group 2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo daily (group 3)
Number of subjects: 37
Study: 11709513

Group type: COMPARATOR
Intervention: Low LCT feed
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High LCT feed
Number of subjects: 54
Study: 9406002

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (Group 1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Visual laser ablation of the prostate (Group 2)
Number of subjects: 23
Study: 12959308

Group type: EXPERIMENTAL
Intervention: Piroximone (0.5 mg kg(‐1); n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg kg(‐1); n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (NaCl as placebo; n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Piroximone and Enoximone
Number of subjects: 30
Study: 2885116

Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Chlordesmethyldiazepam 2 mg daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 30824268

Group type: EXPERIMENTAL
Intervention: Coconut oil (CB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Butter (BB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lard (LB)
Number of subjects: 16
Study: 30139892

Group type: EXPERIMENTAL
Intervention: Individual counselling sessions
Number of subjects: 168
Study: 27044017

Group type: EXPERIMENTAL
Intervention: Interactive school-based program (peer-performed play and school lessons)
Number of subjects: 815

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 815
Study: 25234550

Group type: EXPERIMENTAL
Intervention: 2-mg test tablet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reference tablet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Test tablet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reference Supplemental Table II
Number of subjects: 36
Study: 23800419

Group type: EXPERIMENTAL
Intervention: Imipramine (targeted dose adjusted to 200-300 ng/ml)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Venlafaxine (high-dose, increased to 300-375 mg/day)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Imipramine (in subgroup without psychotic features)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Venlafaxine (in subgroup without psychotic features)
Number of subjects: 85
Study: 20142540

Group type: EXPERIMENTAL
Intervention: Group 1 (shorter acclimatization time)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Group 2 (longer acclimatization time)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 18401987

Group type: EXPERIMENTAL
Intervention: General anesthesia using intravenous or inhaled anesthesia, maintenance with sevoflurane in oxygen and air at variable concentrations to maintain a bispectral index (BIS) between 40 and 60.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: General anesthesia in patients with severe to very severe mental disability.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: General anesthesia in patients with mild to moderate mental disability.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: BIS monitoring during anesthesia.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Anesthetic technique used in the study.
Number of subjects: 47
Study: 19907420

Group type: EXPERIMENTAL
Intervention: 1,500 mg of the ampakine CX717
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.6 mg of naloxone
Number of subjects: 16
Study: 16358864

Group type: EXPERIMENTAL
Intervention: Antibiotics (cefuroxime axetil, clarithromycin) and steroid (prednisone)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Antibiotics (cefuroxime axetil, clarithromycin)
Number of subjects: 116
Study: 12148574

Group type: EXPERIMENTAL
Intervention: Ifosfamide by a 24-hour infusion on day 1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ifosfamide by a 3-hour infusion on days 1-4
Number of subjects: 30
Study: 9548630

Group type: EXPERIMENTAL
Intervention: Case management and peer support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer support group
Number of subjects: 0
Study: 8307444

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg or 40 mg) for 5.7 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no prior antisecretory treatment)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg or 40 mg)
Number of subjects: 25
Study: 3144207

Group type: EXPERIMENTAL
Intervention: Carbohydrate-based diet (CB, 53% carbohydrate)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fat-based diet (FB, 55% fat)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 5% dextrose (D5W) infusion
Number of subjects: 16
Study: 11774069

Group type: EXPERIMENTAL
Intervention: Functional instability of the ankle (14 subjects)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy control subjects (10 subjects)
Number of subjects: 24
Study: 29726013

Group type: EXPERIMENTAL
Intervention: Comprehensive Remote Ischemic Conditioning (CORIC) consisting of per-RIC, post-RIC, and delayed RIC
Number of subjects: 200

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Comprehensive Remote Ischemic Conditioning (CORIC)
Number of subjects: 200